Bristol-Myers Squibb Co logo

BMY - Bristol-Myers Squibb Co Share Price

$61.33 -0.8  -1.2%

Last Trade - 26/02/21

Large Cap
Market Cap £99.48bn
Enterprise Value £124.53bn
Revenue £30.52bn
Position in Universe 83rd / 6715
Unlock BMY Revenue
Relative Strength (%)
1m -2.20%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.68%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
16,560 19,427 20,776 22,561 26,145 42,518 46,328 48,311 +20.8%
-22.3 +117.6 +27.1 +24.5 -37.4 -87.1 +2,345 +7.57
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Bristol-Myers Squibb Co revenues increased 63% to $42.52B.Net loss totaled $9.02B vs. income of $3.44B. Revenuesreflect Prioritized Brands-Revlimid segment increase from$1.3B to $12.11B, Prioritized Brands-Pomalyst/Imnovidsegment increase from $322M to $3.07B, United Statessegment increase of 73% to $26.58B, Europe segment increaseof 57% to $9.85B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BMY
Graphical History


BMY Revenue Unlock BMY Revenue

Net Income

BMY Net Income Unlock BMY Revenue

Normalised EPS

BMY Normalised EPS Unlock BMY Revenue

PE Ratio Range

BMY PE Ratio Range Unlock BMY Revenue

Dividend Yield Range

BMY Dividend Yield Range Unlock BMY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BMY EPS Forecasts Unlock BMY Revenue
Profile Summary

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated August 11, 1933
Public Since July 5, 1929
No. of Shareholders: 36,187
No. of Employees: 30,250
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 2,259,751,518
Free Float (0.0%)
Eligible for
BMY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BMY
Upcoming Events for BMY
Wednesday 5th May, 2021 Estimate
Q1 2021 Bristol-Myers Squibb Co Earnings Release
Frequently Asked Questions for Bristol-Myers Squibb Co
What is the Bristol-Myers Squibb Co share price?

As of 26/02/21, shares in Bristol-Myers Squibb Co are trading at $61.33, giving the company a market capitalisation of £99.48bn. This share price information is delayed by 15 minutes.

How has the Bristol-Myers Squibb Co share price performed this year?

Shares in Bristol-Myers Squibb Co are currently trading at $61.33 and the price has moved by 2.94% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bristol-Myers Squibb Co price has moved by -20.59% over the past year.

What are the analyst and broker recommendations for Bristol-Myers Squibb Co?

Of the analysts with advisory recommendations for Bristol-Myers Squibb Co, there are there are currently 7 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bristol-Myers Squibb Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bristol-Myers Squibb Co next release its financial results?

Bristol-Myers Squibb Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bristol-Myers Squibb Co dividend yield?

The Bristol-Myers Squibb Co dividend yield is 2.93% based on the trailing twelve month period.

Does Bristol-Myers Squibb Co pay a dividend?

Last year, Bristol-Myers Squibb Co paid a total dividend of 1.8, and it currently has a trailing dividend yield of 2.93%. Looking ahead, Bristol-Myers Squibb Co has not announced an ex-dividend date yet.

When does Bristol-Myers Squibb Co next pay dividends?

Bristol-Myers Squibb Co has yet to annouce their ex-dividend date. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 2.93%.

How do I buy Bristol-Myers Squibb Co shares?

To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bristol-Myers Squibb Co?

Shares in Bristol-Myers Squibb Co are currently trading at $61.33, giving the company a market capitalisation of £99.48bn.

Where are Bristol-Myers Squibb Co shares listed? Where are Bristol-Myers Squibb Co shares listed?

Here are the trading details for Bristol-Myers Squibb Co:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: BMY
What kind of share is Bristol-Myers Squibb Co?

Based on an overall assessment of its quality, value and momentum, Bristol-Myers Squibb Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bristol-Myers Squibb Co share price forecast 2021?

Shares in Bristol-Myers Squibb Co are currently priced at $61.33. At that level they are trading at 22.5% discount to the analyst consensus target price of 0.00.

Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of 7.48 for the next financial year.

How can I tell whether the Bristol-Myers Squibb Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, the relative strength of its shares against the market has been -10.12%. At the current price of $61.33, shares in Bristol-Myers Squibb Co are trading at 0.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bristol-Myers Squibb Co PE Ratio?

The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 0.200k. The shares are currently trading at $61.33.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bristol-Myers Squibb Co?

Bristol-Myers Squibb Co's management team is headed by:

Sandra Leung - EVP
Vicki Sato - LED
Giovanni Caforio - CHM
John Elicker - EVP
Ann Judge - CHO
Peter Arduini - IND
Robert Bertolini - IND
Matthew Emmens - IND
Christopher Boerner - EVP
Michael Bonney - IND
Kathryn Metcalfe - EVP
David Elkins - CFO
Nadim Ahmed - EVP
Samit Hirawat - EVP
Elizabeth Mily - EVP
Who are the major shareholders of Bristol-Myers Squibb Co?

Here are the top five shareholders of Bristol-Myers Squibb Co based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.9% (199.3m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.82% (108.1m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.2% (94.2m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.84% (63.7m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 2.33% (52.2m shares)
Similar to BMY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.